key: cord-0711087-7dlo7wky
authors: Popowicz, Grzegorz Maria; Pyrc, Krzysztof; Hadian, Kamyar
title: Vaccination versus SARS-CoV-2 Omicron: three vaccine doses win the battle
date: 2022-04-27
journal: Signal Transduct Target Ther
DOI: 10.1038/s41392-022-01000-3
sha: 89eecdbef869177ac66af1c20b953aaebdc548b3
doc_id: 711087
cord_uid: 7dlo7wky

nan

significantly increased (~2-fold compared to Delta), and the Omicron spike protein is able to escape neutralizing antibodies. This study utilized sera collected from community and healthcare workers with different immunization history-(1) two vaccine doses; (2) two vaccine doses + infection; (3) two vaccine doses + booster shot-and compared their neutralizing activity. Notably, the authors also considered whether the individuals were recently (<3 months) or distantly (6-12 months) vaccinated. The data demonstrate that two doses of COVID-19 vaccines were insufficiently neutralizing Omicron. This observation was similar in recently or distantly double-vaccinated individuals. Only after an additional, third booster dose or an additional infection following the vaccination, sufficient levels of cross-reactive and neutralizing antibodies were produced. The third dose of mRNA-1273 elevated neutralizing capacity by 19-fold, and the third dose of BNT162b by 27-fold. Notably, boosting the immune system with a third spike exposure was more effective upon mRNA vaccination compared to a virus infection. Together, this study reveals that three doses of the vaccine should be recommended to retain protection against SARS-CoV-2 Omicron. 1 Other researchers also investigated the ability of two versus three vaccine shots to neutralize Omicron. Two of these studies have been carried out by Carreño et al. 2 and Wratil et al. 3 . In the study by Carreño et al., the authors analyzed sera from (1) convalescent, (2) mRNA double vaccinated, (3) mRNA triple vaccinated, (4) convalescent plus double vaccinated, and (5) convalescent plus triple vaccinated individuals, and investigated neutralization against Wildtype, Delta and Omicron. This study concluded that convalescent or double vaccinated sera have close to undetectable neutralizing activity against Omicron. All other combinations that had exposed the immune system to the spike antigen three or four times displayed sufficient neutralizing capacity against Omicron; however, this was less pronounced when compared to Wildtype or Delta. 2 Similarly, the study by Wratil et al. investigated neutralizing activity of sera from (1) convalescent and (2) infection-naive individuals prior to vaccination and after first, second, and third BNT162b2 mRNA vaccination. Convalescent or infection-naive individuals with two vaccinations showed good neutralization activity against Alpha, Beta, and Delta. However, while sera from convalescent individuals plus two vaccinations (three exposures) neutralized Omicron, infection-naive individuals with two vaccinations (two exposures) barely neutralized Omicron. Only a third vaccination elevated antibody levels to neutralize Omicron. Hence, also this study demonstrates that three exposures (3x vaccination; or 2x vaccination + 1x infection) are necessary to gain sufficient neutralization activity against Omicron. 3 Together, the here highlighted study by Garcia-Beltran et al. 1 in agreement with the studies by Carreño et al. 2 and Wratil et al. 3 demonstrate that the immune system has to see the spike protein at least three times in order to generate mature neutralizing antibodies with high affinity and avidity to hamper Omicron (Fig. 1) . Interestingly, while an infection plus two vaccinations is enough to neutralize Omicron, three rounds of vaccination may even be better. Based on these studies, there is a clear recommendation for booster vaccination to prepare the immune system to effectively fight Omicron. One limitation of these studies is the relatively short period of observation after the booster dose. It needs to be seen whether neutralizing antibody levels after the third dose may wane over time.

In addition to the necessary three-dose vaccination regimen, drugs will be important to cope with the immune escape of Omicron. Alongside the RNA polymerase inhibitors remdesivir TM and molnupiravir TM , other viral enzymes have been subject to drug development. Especially the viral proteases (M pro and PL pro ) are encouraging drug targets. Paxlovid TM is a recently approved drug to inhibit M pro activity. 4 PL pro inhibitors are still under preclinical development with acriflavine 5 being the most potent. Excitingly, viral protease inhibitors have the potential to provide pan-betacoronavirus activity.

In conclusion, triple-vaccination together with antiviral drugs should provide adequate protection against SARS-CoV-2 Omicron and potential future variants until polyvalent vaccines are developed.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons. 

mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant

Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron

Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern

An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19

Acriflavine, a clinically approved drug, inhibits SARS-CoV-2 and other betacoronaviruses